Roche Holding AG (LON:0QOK)

Market Cap	205.87B
Revenue (ttm)	58.27B
Net Income (ttm)	8.65B
Shares Out	n/a
EPS (ttm)	10.78
PE Ratio	23.79
Forward PE	13.58
Dividend	8.49 (3.29%)
Ex-Dividend Date	Mar 27, 2025

Volume	279,011
Average Volume	170,534
Open	261.80
Previous Close	259.60
Day's Range	256.60 - 263.20
52-Week Range	225.85 - 313.70
Beta	0.17
RSI	47.13
Earnings Date	Jul 24, 2025

About Intra-Cellular Therapies

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn...

• Industry: Pharmaceutical Preparations
• Founded: 1896
• Employees: 103,249
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QOK

Financial Performance

In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.